Dogwood Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses (Tables)

9 Months Ended

Sep. 30, 2022


	September 30,		December 31,
	2022		2021
Accrued compensation	$	261,347	$	532,678
Accrued interest on preferred members’ interests		188,085		188,085
Accrued clinical research costs		379,721		138,522
Accrued director fees		15,500		31,000
Accrued professional fees		103,575		24,100
Other miscellaneous accrued expenses		5,498		7,375
	$	953,726	$	921,760